This trial is testing a new drug to find the best dose and to see if it is safe and tolerated.
- Acute Lymphoblastic Leukemia
- Acute Leukemia
- Acute Myeloid Leukemia
3 Primary · 7 Secondary · Reporting Duration: Up to 2 years and 10 months
1 Treatment Group
1 of 1
110 Total Participants · 1 Treatment Group
Primary Treatment: JNJ-75276617 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
How many individuals have enrolled in this clinical experiment?
"The sponsor, Janssen Research & Development, LLC is responsible for recruiting a total of 110 participants that meet the clinical trial's eligibility requirements. NYU Langone Medical Center in New York City and Cityof Hope in Duarte, California are two of many locations where patients may have access to this medical study." - Anonymous Online Contributor
What is the geographic scope of this clinical investigation?
"This clinical trial is enrolling participants at NYU Langone Medical Center in New York, City of Hope in Duarte, California and the University of California San Francisco located in San Francisco alongside many other sites." - Anonymous Online Contributor
What outcomes is this medical investigation attempting to realize?
"The trial sponsor, Janssen Research & Development LLC, has reported that the primary outcome they will be measuring over a maximal 28 day cycle is Adverse Events (AEs) as an indicator of safety and tolerability. Secondary outcomes include Plasma Concentration of JNJ-75276617, Number of Participants with Depletion of Leukemic Blasts, and Duration of Response (DOR)." - Anonymous Online Contributor
Is there capacity for additional participants in this research endeavor?
"Affirmative. Clinicaltrials.gov records reflect that this medical research, which was initially uploaded on May 19th 2021, is recruiting now. A total of 110 participants need to be enrolled from 8 distinct locations." - Anonymous Online Contributor
Has JNJ-75276617 been accepted by the FDA yet?
"JNJ-75276617 has yet to be fully tested, so our team gave it a 1 on the safety scale. This is because Phase 1 trials are not intended to demonstrate efficacy or provide adequate data regarding its security." - Anonymous Online Contributor